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Abstract
Background: Asthma and atopy are complex phenotypes with shared genetic component. In this study
we attempt to identify genes related to these traits performing a two-stage DNA pooling genome-wide
analysis in order to reduce costs. First, we assessed all markers in a subset of subjects using DNA pooling,
and in a second stage we evaluated the most promising markers at an individual level.
Methods: For the genome-wide analysis, we constructed DNA pools from 75 subjects with atopy and
asthma, 75 subjects with atopy and without asthma and 75 control subjects without atopy or asthma. In a
second stage, the most promising regions surrounding significant markers after correction for false
discovery rate were replicated with individual genotyping of samples included in the pools and an additional
set of 429 atopic subjects and 222 controls from the same study centres.
Results: Homo sapiens protein kinase-like protein SgK493 (SGK493) was found to be associated with
atopy. To lesser extent mitogen-activated protein kinase 5 (MAP3K5), collagen type XVIII alpha 1
(COL18A1) and collagen type XXIX alpha 1 (COL29A1) were also found to be associated with atopy.
Functional evidences points out a role for MAP3K5, COL18A1 and COL29A1 but the function of SGK493 is
unknown.
Conclusion: In this analysis we have identified new candidate regions related to atopy and suggest
SGK493 as an atopy locus, although these results need further replication.
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Background
Asthma and atopy are complex phenotypes with environ-
mental and genetic determinants. Several chromosomal
regions and candidate genes have been implicated in
asthma or atopy susceptibility [1,2]. Genome wide associ-
ation (GWA) studies have been successful in the identifi-
cation of loci contributing to complex diseases, included
asthma [3-5]. However a limitation of GWA studies is the
high economic cost required. A cost-effective alternative is
the use of pooled DNA followed by individual genotyping
[6-8]. In this study, we performed a pooling-based GWA
for asthma and atopy, with further validation of most
promising regions in the individual pooled samples as
well as in a second set of cases and controls.
Methods
Pooling GWA
In the first stage we conducted a GWA analysis using a
DNA-pooling approach. Genotyping was performed
using the Illumina HumanHap 300 Whole-Genome Gen-
otyping BeadChip. The genome-wide analysis was con-
ducted in three different sets of pooled samples: (1)
subjects with atopy and asthma; (2) subjects with atopy
and without asthma, and (3) control subjects with neither
asthma nor atopy (Table 1). Samples for this analysis were
randomly selected from United Kingdom, Spain and Ger-
many cohorts of the European Community Respiratory
Health Survey (ECRHS) study [9]. Atopy was defined as
sensitization (IgE levels >0.35 kU/L) to specific allergens
(D. Pteronyssinus, cat, timothy grass. or C. herbarum).
Asthma was defined as the presence of attacks of asthma
in the last 12 months or taking currently medication for
asthma. All asthmatics subjects had also atopy. For pool
construction, DNA samples were diluted and measured
twice by double stranded DNA quantification using
PicoGreen® dsDNA reagent Kit (Invitrogen), and then nor-
malized at 50 ng/μl. After visual inspection in 0.7% alka-
line agarose gels, selected DNA samples were pooled in
three independent pools of 75 individuals each one. We
have controlled the quality of the Illumina genotyping
process including a sample from HapMap (GM12873)
with known genotype for the panel of 300K markers. We
verified the concordance of genotypes with the HapMap
database (concordance = 99.91%) and inconsistent single
nucleotide polymorphisms (SNPs) were excluded from
the analysis (n = 296, 0.09%). A pool of HapMap (n = 57)
subjects were also performed and genotyped to validate
the allele frequency estimation. SNPs with a poor per-
formance in the estimation of allele frequency were
excluded from the analysis (n = 3271, 1.03%) using a
threshold of > 12% of difference, as shown in previous
reports [7,10], Finally, three replicates of each pool of
ECRHS subjects were constructed to account for sampling
errors in the analysis.
Allele frequencies for each SNP were estimated from
pooled samples correcting by the ratio of intensity of both
alleles [11]. Allele frequencies in each pool were com-
Table 1: Population characteristics of asthma and atopy analyzed samples
Pooling Samples Replication samples
Control Atopy Atopic asthma Control Atopy Atopic asthma subsample
Subjects, n 75 75 75 222 429 198
Subjects excluded*, n (%) 14 (19) 17 (23) 14 (19) 47 (21) 98 (23) 48 (24)
Age, mean (sd) 35.87 (6.79) 32.21 (7.78) 32.07 (6.95) 35.36 (7.16) 33.32 (7.15) 33.19 (7.14)
Gender
Males, n (%) 37 (49) 38 (51) 37 (49) 106 (48) 205 (48) 84 (42)
Females, n (%) 38 (51) 37 (49) 38 (51) 116 (52) 224 (52) 114 (58)
Smoking
Current, n (%) 19 (25) 23 (31) 28 (38) 56 (25) 100 (23) 37 (19)
Ex, n (%) 20 (27) 18 (24) 16 (22) 58 (26) 96 (22) 47 (24)
Never, n (%) 36 (48) 34 (45) 30 (41) 107 (48) 232 (54) 114 (58)
*Subjects excluded at the individual genotyping (stage 2)BMC Medical Genetics 2009, 10:128 http://www.biomedcentral.com/1471-2350/10/128
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pared using the 1 df chi-square T statistic for testing differ-
ences between two proportions accounting for
experimental and sampling errors [11]. Multiple testing
was controlled using a false discovery rate (FDR) at 5%
[12]. Allele frequency estimation was validated using a
pool of 57 samples from HapMap whose individual gen-
otypes for 300K Illumina panel were previously known.
Predicted and real allele frequencies showed a strong cor-
relation (Pearson correlation coefficient, r = 0.99).
Individual genotyping in ECHRS
In a second stage, replication was performed by individual
genotyping of subjects included in the pools (n = 225)
and in an additional set of 429 atopic subjects (46% with
asthma) and 222 controls subjects randomly selected
from the ECRHS study. Only promising SNPs that were
still significant after correction by multiple testing were
followed up. Target regions were delimited by non signif-
icant SNPs (p > 0.05) upstream and downstream from the
SNP significant associated after multiple testing correc-
tions in the first stage (see Additional file 1: table S1).
Complex regions with genomic structural variants were
discarded for this study (chr 1 and chr 5) [13]. For the sat-
uration we used a tag SNP approach forcing the inclusion
of the polymorphisms detected in the first stage, or their
perfect tags (r2 ≥ 0.8). From the HapMap project data set,
we utilized genotypes from the public release 21a (phase
II; NCBI35, dbSNPb125) corresponding to 90 individuals
from the CEPH 30 trios of European descent. The selec-
tion of tag SNPs was performed using the pair-tagging
strategy implemented in Haploview software (v.4.0) with
a MAF ≥ 0.05 and an r2 ≥ 0.8 [14]. In addition to HapMap
SNPs, four other polymorphisms previously described to
be associated with atopic dermatitis and situated in one of
the targeted regions (COL29A1) were included [15]. The
53 SNPs selected were genotyped in individual samples
using SNPlex technology (Applied Biosystems).
Genotyping quality was controlled by including negative
controls and internal positive controls consisting in four
replicates of two HapMap reference samples. Both, geno-
type concordances with the HapMap database and among
replicates, were verified. Genotype data caring was done
using SNP analysis to results software (SNPator) http://
www.snpator.com/. Forty-five out of 225 pooled samples
and 145 out of 651 replication samples were dropped
from the individual analysis due to low volume of DNA
available or low concentration (Table 1). Seven out of 53
genotyped SNPs were excluded from the analysis since
deviation from Hardy-Weinberg equilibrium (HWE) (in
controls p < 0.05) or showed a genotyping rate under
80%. The final replication set included 46 SNPs with an
overall genotyping rate of 97% in 686 samples (Table 1).
Genotyping assays were performed at the Barcelona Node
of the "Centro Nacional de Genotipado" (CeGen) in
Spain.
The statistical analysis for data derived from individual
genotyping was performed assuming an additive genetic
model and using logistic regression using R statistical soft-
ware package [16]. Models were adjusted for age, sex and
smoking status. Country of origin was considered in the
regression models in order to discard confounding by
population stratification [17]. Linkage disequilibrium
(LD) blocks were estimated according to Gabriel et al.
[18] method implemented in Haploview.
SGK493 tissue expression
A human RNA tissue panel (Stratagene) including brain,
heart, kidney, liver, lung, placenta, skeletal muscle,
spleen, testis, ovary and thymus was used to evaluate the
expression of SGK493. One μg of RNA was converted to
cDNA using the SuperScript III First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen). SGK493 and the GAPDH
genes were amplified in independent PCRs using the fol-
lowing primers SGK493-F: 5'-AAGTGACGGACCTGGAT-
GAC-3' and SGK493-R: 5'-TGTGAGGCAG GAGG TAT GT
G-3' and GAPDH-F: 5'-ACCCAGAAGACTGTGGA TGG-3'
and GAPDH-R: 5'-TGCTGTAGCCAAATTCGTTG-3'. The
expected fragment sizes according to hg18 are 189 bp and
415 bp, respectively. The PCR was performed on a final
volume of 25 μl using 0.5 U of BioTherm DNA polymer-
ase (GeneCraft), 2 mM of Mg, 50 μM of each dNTP, 0.12
μM of each primer and 1 μl or 0.5 ul of cDNA (SGK493
and GAPDH, respectively). Finally 10 μl of the SGK493
PCR and 5 μl of the GAPDH PCR were resolved on a 2%
agarose gel.
The study was conducted in accordance with the Declara-
tion of Helsinki Principles. Ethical approval was obtained
for each centre from the appropriate institutional ethics
committee and all subjects participating in this study pro-
vided informed consent.
Results
Pooling GWA
A genome wide analysis was performed with three pools
of DNA from atopic, atopic asthmatics and control indi-
viduals. Population characteristics are shown in Table 1.
Significant results after correction for 5% FDR in the GWA
of pooled DNA are shown in Table 2 (see Additional file
1: table S1 for the genome-wide surrounding SNPs).
Seven SNPs were associated with atopy and one with
atopic asthma. From these results, five regions were
selected for individual genotyping at a second stage. Three
of these regions contained genes putatively related to
asthma or atopy: collagen type XXIX alpha 1 (COL29A1,
also known as COL6A5, a new member of the collagen
family [19]), mitogen-activated protein kinase kinase
kinase 5 (MAP3K5, also known as apoptosis signal-regu-
lating kinase 1 (ASK1)), collagen type XVIII alpha 1
(COL18A1) and solute carrier family 19 member 1
(SLC19A1). The other two regions contained genes forBMC Medical Genetics 2009, 10:128 http://www.biomedcentral.com/1471-2350/10/128
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which no obvious functionality could be inferred: Homo
sapiens protein kinase-like protein SgK493 (SGK493) and
a predicted gene in chromosome 8 (NT_007995.50)
which presented two consecutive SNPs associated with
atopy in the pooled analysis. Additional SNPs surround-
ing these six markers were genotyped at an individual
level (see Additional file 1: table S2, for the results of the
53 SNPs genotyped at an individual level).
Individual genotyping
A summary of the positive results on individual samples
for atopy is shown in Table 3. SNPs found to be significant
for atopy at individual level in both pooling samples and
replication set were located in SGK493  and  MAP3K5
genes. Variants in COL18A1 and COL29A1 were not con-
sistently replicated in both samples, although a variant in
the COL18A1 (at 5' of the SLC19A1 region) was signifi-
Table 2: SNPs associated with asthma or atopy with a FDR of 5% in the pooling-based GWA
SNP Chromosome Position Comparison p value fAco-fAca Region Saturation
rs2501618 1 178225432 Atopy vs. controls 1.26 × 10-7 0.26 CEP350 No
rs4952590 2 42130425 Atopy vs. controls 4.63 × 10-7 0.19 SGK493 (LOC91461) Yes
rs7629719 3 131642624 Atopy-Asthma vs. controls 1.11 × 10-7 0.21 COL29A1 (COL6A5) Yes
rs9292961 5 20975886 Atopy vs. controls 5.38 × 10-7 0.3 Segmental Duplications No
rs9376221 6 137034072 Atopy vs. controls 3.94 × 10-7 0.25 MAP3K5 (ASK1) Yes
rs7843085 8 33235086 Atopy vs. controls 3.93 × 10-7 0.26 NT_007995.50 Yes
rs13273924 8 33246541 Atopy vs. controls 7.56 × 10-7 0.26 NT_007995.50 Yes
rs2330183 21 45777720 Atopy vs. controls 1.59 × 10-7 0.28 SLC19A1 Yes
fAco (allele frequency in controls); fAca (allele frequency in cases); CEP350: centrosomal protein 350 kDa; SGK493: protein kinase-like protein 
SgK493; COL29A1: collagen, type XXIX, alpha 1; MAP3K5: mitogen-activated protein kinase kinase kinase 5; ASK1: apoptosis signal-regulating kinase 
1; SLC19A1: solute carrier family 19 (folate transporter), member 1
Table 3: Summary of the SNPs significantly associated with atopy at an individual level
ECHRS Atopy vs. controls
SNP Gene MAF Chromosome Position (build36) Pooling Replication Combined
rs11124858* SGK493 0.367 2 42113828 0.0021 0.0318 0.0007†
rs13409978* SGK493 0.122 2 42119206 0.0007† 0.0124 0.0001†
rs4952590** SGK493 0.141 2 42130425 0.0001† 0.0008† 1.9 × 10-6†
rs1440095 SGK493 0.379 2 42143170 0.0098 0.1078 0.0105
rs10934938 COL29A1 0.23 3 131596325 0.1158 0.0291 0.0056
rs9402839* MAP3K5 0.138 6 137036903 0.0355 0.0524 0.0099
rs9494554** MAP3K5 0.095 6 137038675 0.0306 0.0035 0.0005†
rs12483377* COL18A1 0.108 21 45755537 0.0046 0.0607 0.0030
*SNPs found associated in the pooling-based GWA or their perfect tags (r2 = 0.8) used as substitutes in the genotyping design.
**SNPs that remained significant after a 5% FDR in the pooling-based GWA
†P-values that remain significant after Bonferroni correction (46 SNPs, p ≤ 0.001)BMC Medical Genetics 2009, 10:128 http://www.biomedcentral.com/1471-2350/10/128
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cant in pooling samples (p = 0.005) and border signifi-
cant in the replication (p = 0.06). For variants listed in
Table 3, the combined analysis of samples from pooling
and the additional case control set, led to lower p values,
indicating that genetic effects are in the same direction in
both sets [20].
The region in chromosome 2 containing the SGK493 gene
showed the SNPs with the most significant p values in the
association with atopy, and similar results were observed
for the subset of atopic individuals with asthma (see Addi-
tional file 1: table S2). The variant rs4952590 remain sig-
nificant even after Bonferroni correction (46 SNPs, p ≤
0.001) in the both pooling and replication samples. This
variant was associated with a reduction in risk of atopy in
both samples (odds ratio (OR) = 0.18, 95% confidence
interval (CI) 0.07-0.47 for pooling sample and OR = 0.52,
95%CI 0.35-0.79 for replication sample). In addition, var-
iant rs13409978 in the pooling sample and three SNPs
(rs11124858, rs13409978, rs4952590) remained signifi-
cant in the combined analysis after Bonferroni correction.
Figure 1 shows the representation of the linkage disequi-
librium (LD) pattern for the 6 SNPs of SGK493 genotyped
for all individuals of the sample (n = 699). Two blocks of
disequilibrium were defined according to Gabriel et al.
[18] method implemented in Haploview. Complete LD
pattern of the region derived from HapMap data is sum-
marized in the Additional file 1: figure S1. Haplotype
analysis using the six SNPs (Table 4) confirms the results
obtained in the single marker analysis. The only haplo-
type containing C allele of rs13409978 and T allele of
rs4952590 is the only significantly associated with atopy
(p = 0.00005). These SNPs are in high LD (D'= 0.97 and
r2 = 0.88). The expression pattern of SGK493 presented in
Figure 2 shows that SGK493 is ubiquitously expressed in
all the human tissues analyzed.
The intronic SNP rs9494554, located within MAP3K5,
was associated with atopy in the pooling and replication
samples, and remained significant in the combined anal-
ysis after Bonferroni correction. A similar association for
rs9494554 was observed in the subsample of atopic asth-
matic individuals (see Additional file 1: table S2). Other
SNP in MAP3K5 (rs9402839) was nominally significant
for atopy in pooling sample and border significant in the
replication step.
Discussion
We performed a two-stage DNA pooling-based GWA for
asthma and atopy, evaluating a genome-wide panel of
markers in a subset of subjects using a DNA pooling strat-
egy, and in a second stage we evaluated the most promis-
ing markers at an individual level in the individual pooled
samples as well as in a second set of cases and controls.
We identified SGK493 as a new potential gene associated
to atopy. MAP3K5, COL18A1 and COL29A1 genes were
found to lesser extent associated with atopy.
The most significant results were observed for SGK493
gene, in chromosome 2, with similar results for atopy and
for atopic asthma, probably due to sharing predisposing
factors [1]. Significant polymorphisms were located in
two different linkage disequilibrium blocks. The first
block includes the putative promoter region of SGK493
(5' upstream) and the second block covers part of the gene
and the 3' untranslated region (UTR) and 3'downstream
region (Figure 1). Haplotype based analysis confirmed
results obtained in single marker analysis. We could not
elucidate which is the functionality of these SNPs and a
fine mapping of the region within a more powered sample
would be required. We cannot exclude that the functional
variant could be tagged by these SNPs and located in
another close gene. SGK493 gene was identified during
the creation of a catalogue of human protein kinases [21],
but its particular function is unknown. SGK493 could be
involved in pathological states as protein kinases mediate
most of the signal transduction in eukaryotic cells [22].
We reported that SGK493 gene is ubiquitously expressed
in human tissues, however a higher expression on lung
and uterus was previously identified by microarray exper-
iment from 73 human tissues http://biogps.gnf.org/[23].
Recently, the knock out of Sgk493 (also known as Pkdcc)
in mouse has been described presenting extreme pheno-
types that are not a priori related with atopy or asthma.
Table 4: Haplotype analysis and multiple regression for SGK493 gene variants.
rs11124858 rs13409978 rs17029121 rs4952590 rs2424 rs1440095 Frequency p-value
AAAC A T 0 . 3 6 r e f e r e n c e
* * G ** *0 . 2 2 0 . 1 2 8
G * * * T C 0.17 0.506
G C * T * C 0.12 0.00005
* Same allele to reference haplotype (most frequent)BMC Medical Genetics 2009, 10:128 http://www.biomedcentral.com/1471-2350/10/128
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The knock out mice showed abnormal respiration and
died within a day possibly due to cleft palate [24].
Another kinase MAP3K5 was also related to atopy as well
as atopic asthma in this study. MAP3K5 encodes for a
member of the mitogen-activated protein kinase family
that regulates the activation of the transcription factor
activator protein-1 (AP1) in leukotriene D (4) (LTD(4))
stimulated airway smooth muscle cells and in nitric oxy-
gen (NO) stimulated bronchial epithelial cells [25,26].
AP1 play a role in the production of airway inflammation
[26].
Polymorphisms in COL18A1 and COL29A1 were not con-
sistently replicated. The COL18A1 polymorphism shown
to be significantly associated with atopy in the pooling
sample is located at the 3' coding region of the gene.
COL18A1 encodes a protein expressed in epithelial and
endothelial basement membranes, involved in regulation
of angiogenesis and endothelial cell proliferation [27-29].
The COL29A1 polymorphism was previously found to be
associated with atopic dermatitis [15]. Finally, a region
situated in chromosome 8, which contains a predicted
gene (NT_007995.50), was also analyzed in detail. Nom-
inally associations were observed in the pooling sample
for atopy, but they were not replicated.
Signals described in previous GWA for atopy, asthma and
related phenotypes have not been detected in this study
[3-5]. The lack of replication of the GWA results can be
caused by differences in the definition used to classify
affected individuals, genetic coverage of the genome and
the p value threshold [30]. In particular, the region
detected by Moffatt et al[3] on chromosome 17 has been
associated with childhood onset asthma, while in this
study the asthmatic individuals were selected independ-
ently of their asthma onset. We have not detected the
FCER1A region identified by Weidinger et al[5] for atopy,
but a different genotyping platform was used.
Despite significant replication values of most promising
SNPs found in the GWA in pooled DNA, we acknowledge
some limitations as the lack of replication for some of the
loci identified in the pooling based analysis. Non-replica-
tion of the initial findings is a common feature of the ini-
tial findings in GWA studies [31], mainly due to
heterogeneity in the aetiology of the disease and biases. In
addition, the impossibility of detection and adjustment
by potential confounders in the analysis of DNA pooling
could produce the inconsistencies observed.
Another of the main limitation is the sample size for pool
construction and replication. Regarding DNA pooling, the
method for measure allele frequency differences corrects
by the number of subjects included in each pool [11].
After this correction we obtained some signals at very low
p-values, which reinforce the strength of these results.
Given limited sample, our study was able to detect vari-
ants with larger effects in this population and probably
other variants with smaller effects would not be detected.
False positives are controlled in the replication phase by
individual analysis. Other pooling strategies such as use of
different sub-samples of pools would allow capture more
biological variation. We acknowledge that with having
larger pools we may be losing positive signals but we con-
sider this as a less crucial issue for this analysis. Power cal-
culation shows that replication sample was powered to
detect reported associations given the parameters
observed in the analysis of individual pooling data (see
Additional file 1: table S3). For this reason, some of the
results were replicated and significance for a SNP in
SGK493 reaches Bonferroni level. Although this type of
correction by multiple testing is over-conservative and
induces false negatives, it is a good indicator of the signif-
icance level. In addition to the significance level, some of
Linkage disequilibrium pattern and haplotype blocks of SNPs  in the SGK493 gene using genotyping data in this study Figure 1
Linkage disequilibrium pattern and haplotype blocks 
of SNPs in the SGK493 gene using genotyping data in 
this study. Colors correspond to D' and numbers in each 
cell to r2 parameter. Blocks were defined with method 
described by Gabriel et al. [18]. In red is marked the coding 
region of the SGK493 gene (lines are introns and boxes 
exons) and blue boxes show the untranslated (UTR) regions 
of the gene. * SNPs found associated in the individual pooled 
samples and replication sample (Table 3).BMC Medical Genetics 2009, 10:128 http://www.biomedcentral.com/1471-2350/10/128
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the results were replicated in the additional sample and
replication is considered essential to establish the validity
of associations [32].
Finally, another limitation is the small number of regions
analyzed in detail in the individual analysis. We discarded
complex regions with segmental duplications and puta-
tive insertions or deletions [13] because their complexity
could a priori result in reducing power to detect associa-
tions due to non-classical inheritance patterns of markers
located on them. In contrast, disease definition is a posi-
tive feature of this study since it is highly homogeneous
among patients derived from different ECHRS centre, and
this is a keystone for valid inferences in association stud-
ies.
Conclusion
In summary, we identified a region related to atopy on
chromosome 2p21 that contains SGK493 gene. A non-
synonymous SNP in COL18A1, intronic variants in
MAP3K5 and a polymorphism in COL29A1, previously
related to atopic dermatitis, were also associated with
atopy, but not consistently replicated. Follow-up analysis
in larger sample sets, as well fine mapping will be needed
to validate these susceptibility loci.
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